Roche has received US Food and Drug Administration approval for a new pharmacogenetic indication for the non-small cell lung cancer drug Tarceva (erlotinib) and a companion test that picks out best responders to the treatment.

The agency announced this week that it had approved Roche's Cobas EGFR Mutation test as a companion diagnostic for Tarceva when it is given as a first-line treatment for metastatic NSCLC patients whose tumors harbor certain EGFR mutations.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Genome Research this week: multiplex genotyping of germline and somatic short tandem repeats, graph-based regularization, and more.

A lack of funding may lead more than two dozen research facilities in Australia to shut down in three months.

Researchers report that paternally inherited genes are more likely to be expressed in mice.

In PNAS this week: Akt3 amplification in glioma progression, Tibetan Plateau frog genome, and more.